Exact Sciences says the $190 million acquisition of Marshfield-based PreventionGenetics will expand its cancer diagnostics capabilities.

The move also sets up the Madison company’s entrance into the field of hereditary cancer testing, which focuses on detecting heritable genetic mutations that could increase the risk of developing certain cancers.

“With our deep relationships in primary care and PreventionGenetics’ strong reputation among genetics specialists, Exact Sciences can help more people understand their inherited risk of cancer to catch it earlier and treat it more effectively,” Kevin Conroy, the company’s chairman and CEO, said in a statement.

Click here to read the full article.